文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

人重组碱性磷酸酶对脓毒症相关急性肾损伤患者7天肌酐清除率的影响:一项随机临床试验

Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01
一句话结论在脓毒症相关急性肾损伤危重患者中,与安慰剂相比,人重组碱性磷酸酶未显著改善短期肾功能(第1-7天平均每日肌酐清除率绝对差异9.5 mL/min,95%CI -23.9至25.5,P=0.47)。

STOP-AKI试验为国际多中心(53个招募中心)、随机、双盲、安慰剂对照、剂量探索、适应性2a/2b期研究,纳入301例ICU脓毒症合并AKI成人患者。第一部分随机接受0.4、0.8、1.6 mg/kg重组碱性磷酸酶或安慰剂,每日一次,共3天;基于建模和不良事件确定最佳剂量为1.6 mg/kg。第二部分比较1.6 mg/kg(n=82)与安慰剂(n=86)。主要终点第1-7天经时间校正的内源性肌酐清除率曲线下面积除以7(平均每日肌酐清除率),1.6 mg/kg组从26.0 mL/min升至65.4 mL/min,安慰剂组从35.9 mL/min升至61.9 mL/min,绝对差异9.5 mL/min(95%CI -23.9至25.5;P=0.47),无显著差异。致死性不良事件发生率在0.4 mg/kg组26.3%、0.8 mg/kg组17.1%、1.6 mg/kg组17.4%、安慰剂组29.5%;非致死性严重不良事件发生率分别为21.0%、14.3%、25.7%、20.5%。结论认为人重组碱性磷酸酶未显著改善短期肾功能,需进一步研究评估其他临床结局。

要点

  • 在脓毒症相关AKI危重患者中,人重组碱性磷酸酶1.6 mg/kg每日一次共3天,第1-7天平均每日肌酐清除率与安慰剂无显著差异(绝对差异9.5 mL/min,95%CI -23.9至25.5;P=0.47)。
  • 致死性不良事件发生率:0.4 mg/kg组26.3%、0.8 mg/kg组17.1%、1.6 mg/kg组17.4%、安慰剂组29.5%;非致死性严重不良事件:0.4 mg/kg组21.0%、0.8 mg/kg组14.3%、1.6 mg/kg组25.7%、安慰剂组20.5%。
  • 最佳剂量1.6 mg/kg基于建模方法和不良事件确定,并非基于疗效优于其他剂量。
  • 研究纳入301例成人ICU脓毒症合并AKI患者,男性70.7%,中位年龄67岁(IQR 59-73)。
  • 作者结论:人重组碱性磷酸酶与安慰剂相比未显著改善短期肾功能,需进一步研究评估其他临床结局。

适用人群与场景

  • 成人ICU患者,诊断为脓毒症和急性肾损伤(AKI)。
  • 纳入301例,男性70.7%,中位年龄67岁(IQR 59-73)。

处置流程与药物剂量

  • 第一部分:随机接受重组碱性磷酸酶0.4 mg/kg(n=31)、0.8 mg/kg(n=32)、1.6 mg/kg(n=29)或安慰剂(n=30),每日一次,共3天,以确定最佳剂量。
  • 第二部分:1.6 mg/kg(n=82)与安慰剂(n=86)比较。
  • 最佳剂量确定为1.6 mg/kg,基于建模方法和不良事件。

研究设计与关键结果

  • 研究类型:国际(53个招募中心)、随机、双盲、安慰剂对照、剂量探索、适应性2a/2b期研究;纳入301例成人ICU脓毒症合并AKI患者;2014年12月至2017年5月入组,随访90天,末次随访2017年8月14日。
  • 主要终点:第1-7天经时间校正的内源性肌酐清除率曲线下面积除以7(平均每日肌酐清除率)。1.6 mg/kg组从26.0 mL/min(IQR 8.8-59.5)升至65.4 mL/min(IQR 26.7-115.4),安慰剂组从35.9 mL/min(IQR 12.2-82.9)升至61.9 mL/min(IQR 22.7-115.2),绝对差异9.5 mL/min(95%CI -23.9至25.5;P=0.47),无显著差异。
  • 致死性不良事件:0.4 mg/kg组26.3%、0.8 mg/kg组17.1%、1.6 mg/kg组17.4%、安慰剂组29.5%。
  • 非致死性严重不良事件:0.4 mg/kg组21.0%、0.8 mg/kg组14.3%、1.6 mg/kg组25.7%、安慰剂组20.5%。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照、适应性2a/2b期研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒症相关AKI危重患者中,人重组碱性磷酸酶与安慰剂相比未显著改善短期肾功能,作者结论认为需进一步研究评估其他临床结局。

指南或共识出处

  • STOP-AKI试验,ClinicalTrials.gov标识符NCT02182440。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sepsis-associated acute kidney injury (AKI) adversely affects long-term kidney outcomes and survival. Administration of the detoxifying enzyme alkaline phosphatase may improve kidney function and survival.

OBJECTIVE: To determine the optimal therapeutic dose, effect on kidney function, and adverse effects of a human recombinant alkaline phosphatase in patients who are critically ill with sepsis-associated AKI.

DESIGN, SETTING, AND PARTICIPANTS: The STOP-AKI trial was an international (53 recruiting sites), randomized, double-blind, placebo-controlled, dose-finding, adaptive phase 2a/2b study in 301 adult patients admitted to the intensive care unit with a diagnosis of sepsis and AKI. Patients were enrolled between December 2014 and May 2017, and follow-up was conducted for 90 days. The final date of follow-up was August 14, 2017.

INTERVENTIONS: In the intention-to-treat analysis, in part 1 of the trial, patients were randomized to receive recombinant alkaline phosphatase in a dosage of 0.4 mg/kg (n = 31), 0.8 mg/kg (n = 32), or 1.6 mg/kg (n = 29) or placebo (n = 30), once daily for 3 days, to establish the optimal dose. The optimal dose was identified as 1.6 mg/kg based on modeling approaches and adverse events. In part 2, 1.6 mg/kg (n = 82) was compared with placebo (n = 86).

MAIN OUTCOMES AND MEASURES: The primary end point was the time-corrected area under the curve of the endogenous creatinine clearance for days 1 through 7, divided by 7 to provide a mean daily creatinine clearance (AUC1-7 ECC). Incidence of fatal and nonfatal (serious) adverse events ([S]AEs) was also determined.

RESULTS: Overall, 301 patients were enrolled (men, 70.7%; median age, 67 years [interquartile range {IQR}, 59-73]). From day 1 to day 7, median ECC increased from 26.0 mL/min (IQR, 8.8 to 59.5) to 65.4 mL/min (IQR, 26.7 to 115.4) in the recombinant alkaline phosphatase 1.6-mg/kg group vs from 35.9 mL/min (IQR, 12.2 to 82.9) to 61.9 mL/min (IQR, 22.7 to 115.2) in the placebo group (absolute difference, 9.5 mL/min [95% CI, -23.9 to 25.5]; P = .47). Fatal adverse events occurred in 26.3% of patients in the 0.4-mg/kg recombinant alkaline phosphatase group; 17.1% in the 0.8-mg/kg group, 17.4% in the 1.6-mg/kg group, and 29.5% in the placebo group. Rates of nonfatal SAEs were 21.0% for the 0.4-mg/kg recombinant alkaline phosphatase group, 14.3% for the 0.8-mg/kg group, 25.7% for the 1.6-mg/kg group, and 20.5% for the placebo group.

CONCLUSIONS AND RELEVANCE: Among patients who were critically ill with sepsis-associated acute kidney injury, human recombinant alkaline phosphatase compared with placebo did not significantly improve short-term kidney function. Further research is necessary to assess other clinical outcomes.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02182440.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Pickkers P, Mehta RL, Murray PT, et al. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2018. PMID: 30357272. doi:10.1001/jama.2018.14283

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。